Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 5/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CCR2 | P41597 | 5/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7670332 | 0.82 | DAO (0.70) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL7108 | 0.81 | LDHA (0.82) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL7814 | 0.80 | LDHA (1.00) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL13308 | 0.80 | LDHA (1.00) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL7300 | 0.80 | LDHA (1.00) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL2940271 | 0.80 | DAO (0.67) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL30305558 | 0.80 | DAO (0.67) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL2157437 | 0.78 | DAO (0.65) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL3638561 | 0.78 | DAO (0.65) | DAOLDHAMCL1ALDH1A1TSHR | |
| SCHEMBL2868490 | 0.78 | DAO (0.65) | DAOLDHAMCL1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105866303-A | Detecting method for determining various neurotransmitters on the basis of in situ derivation | 曲阜师范大学 | 2016-08-17 | — | — | CN | disclosed |
| US-20140343001-A1 | INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) | UNIVERSITA DI PISA (IT) | 2014-11-20 | — | — | US | disclosed |
| WO-2013092753-A1 | INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) | UNIVERSITÀ DI PISA (IT) | 2013-06-27 | — | — | WO | disclosed |
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITÀ DI PISA (IT) | 2012-12-06 | — | — | US | disclosed |
| EP-2499114-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Universita Di Pisa (IT) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011054525-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITA' DI PISA (IT) | 2011-05-12 | — | — | WO | disclosed |
| EP-2231666-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076631-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-2038254-A2 | BICYCLIC COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | Kinex Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20060016024-A1 | Novel coupling components | PARALLEL WIRELESS, INC. | 2006-01-26 | — | — | US | disclosed |
| CN-1067988-C | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 2001-07-04 | — | — | CN | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5643672-A | Cosmetic composition containing solid particles coated with an amphoteric polymer | L'OREAL (FR) | 1997-07-01 | — | — | US | disclosed |
| CN-1136038-A | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 1996-11-20 | — | — | CN | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| CN-1106800-A | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 1995-08-16 | — | — | CN | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LDHA, LDHB, DLD | DAO 565/4885LDHA 1/4885MCL1 1571/4885 |
| US-20140343001-A1 | INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) | LDHA, LDHB, IDO1 | DAO 176/4885LDHA 1/4885MCL1 418/4885 |
| US-20060016024-A1 | Novel coupling components | KRT18, H1-4, H1-3 | DAO 429/4885LDHA 3438/4885MCL1 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.